A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTI-CENTER STUDY TO EVALUATE T

$366M01FY2009RRNIH

University Of Minnesota, Minneapolis MN

Investigators

Linked publications & trials

Paper 38621411 Paper 37935316 Paper 37717845 Paper 37074026 Paper 36920087 Paper 35843468 Paper 35275227 Paper 35012890 Paper 34699464 Paper 34421369 Paper 34133774 Paper 33512723 Paper 33301877 Paper 32492148 Paper 31768127 Paper 31448444 Paper 30677258 Paper 30674623 Paper 30287050 Paper 30103017 Paper 30101556 Paper 29563196 Paper 29513264 Paper 29197678 Paper 29164254 Paper 28702218 Paper 28616384 Paper 28549539 Paper 28053319 Paper 27917600 Paper 27492803 Paper 27465220 Paper 27208344 Paper 27100471 Paper 27019570 Paper 26838526 Paper 26823646 Paper 26692253 Paper 26689837 Paper 26676824 Paper 26601918 Paper 26510851 Paper 26427963 Paper 26385402 Paper 26375197 Paper 26336066 Paper 26307644 Paper 26251515 Paper 26241065 Paper 26220198 Paper 26163815 Paper 26095521 Paper 26089309 Paper 26077017 Paper 25865649 Paper 25798622 Paper 25689602 Paper 25642774 Paper 25627625 Paper 25596104 Paper 25562486 Paper 25541100 Paper 25465411 Paper 25453541 Paper 25448532 Paper 25422964 Paper 25327738 Paper 25307304 Paper 25266246 Paper 25256555 Paper 25127083 Paper 24999423 Paper 24996508 Paper 24990328 Paper 24954303 Paper 24939426 Paper 24934193 Paper 24893607 Paper 24834977 Paper 24770450 Paper 24763405 Paper 24745476 Paper 24722251 Paper 24683420 Paper 24594903 Paper 24577876 Paper 24568669 Paper 24560492 Paper 24529364 Paper 24406375 Paper 24386612 Paper 24333913 Paper 24296850 Paper 24196015 Paper 24124194 Paper 24121211 Paper 24118416 Paper 24050942 Paper 24026563 Paper 24009155

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to examine prospectively the safety and efficacy of alefacept in the treatment of subjects with severe alopecia areata of the scalp. Common features between psoriasis and alopecia areata, including immunologic and thereapeutic aspects, suggests that alefacept, which has been shown to be a safe and statistically significant beneficial therapeutic modality for the treatment of psorasis, may have thereapeutic value in alopecia areata.

View original record on NIH RePORTER →